Eudragit® microparticles for the release of budesonide: A comparative study

Indian Journal of Pharmaceutical Sciences

Volumn 74, Issue 5, 2012, Pages 415-421

  Cortesi, Rita ^a   Ravani, Laura ^a   Menegatti, Enea ^a   Esposito, Elisabetta ^a   Ronconi, F ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Budesonide; controlled release; Crohn's disease; microparticles

Indexed keywords

BUDESONIDE; EUDRAGIT; MICROSPHERE;

ARTICLE; CONTROLLED STUDY; DRUG RELEASE; DRUG STABILITY; IN VITRO STUDY; INTESTINE FLUID; NONHUMAN; SIMULATION; STOMACH PH; THERMOSTABILITY;

EID: 84875965089     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.108416     Document Type: Article

References (28)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
2. Philip AK, Philip B. Colon targeted drug delivery systems: A review on primary and novel approaches. Oman Med J 2010;25:79-87.
3. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43.
4. Crotty B, Hoang P, Dalton HR, Jewell DP. Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression. Gut 1992;33:59-64.
5. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
6. Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
7. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209-14.
8. Edsbäcker S, Larsson P, Wollmer P. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. Eur J Gastroenterol Hepatol 2002;14:1357-62.
9. Krishnamachari Y, Madan P, Lin S. Development of pH-and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm 2007;338:238-47.
10. Martin TM, Bandi N, Shulz R, Roberts CB, Kompella UB. Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS Pharm Sci Tech 2002;3:E18.
11. Crcarevska MS, Dodov MG, Petrusevska G, Gjorgoski I, Goracinova K. Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis. J Drug Target 2009;17:788-802.
12. Kadian SS, Harikumar SL. Eudragit and its pharmaceutical significance. PharmainfoNet, 2009. Available from: http://www.pharmainfo.net/ satishsinghkadian/publications/eudragit-and-its-pharmaceutical-significance. [Last accessed 2 Sep 2012].
13. Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Eudragit-coated pectin microspheres of 5-fluorouracil for colon targeting. AAPS Pharm Sci Tech 2007;8:12.
14. Esposito E, Sebben S, Cortesi R, Menegatti E, Nastruzzi C. Preparation and characterization of cationic microspheres for gene delivery. Int J Pharm 1999;189:29-41.
15. Esposito E, Roncarati R, Cortesi R, Cervellati F, Nastruzzi C. Production of Eudragit microparticles by spray-drying technique: Influence of experimental parameters on morphological and dimensional characteristics. Pharm Dev Technol 2000;5:267-78.
16. Jantratid E, Janssen N, Chokshi H, Tang K, Dressman JB. Designing biorelevant dissolution tests for lipid formulations: Case example-Lipid suspension of RZ-50. Eur J Pharm Biopharm 2008;69:776-85.
17. Palmieri GF, Bonacucina G, Di Martino P, Martelli S. Spray-drying as a method for microparticulate controlled release systems preparation: Advantages and limits. I. Water-soluble drugs. Drug Dev Ind Pharm 2001;27:195-204.
18. Cortesi R, Esposjto E, Luca G, Nastruzzi C. Production of lipospheres as carriers for bioactive compounds. Biomaterials 2002;23:2283-94.
19. Esposito E, Cortesi R, Luca G, Nastruzzi C. Pectin-based microspheres: A preformulatory study. Ann N Y Acad Sci 2001;944:160-79.
20. Jyothi NV, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS, Srawan GY. Microencapsulation techniques, factors influencing encapsulation efficiency. J Microencapsul 2010;27:187-97.
21. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res 2008;25:999-1022.
22. Esposito E, Menegatti E, Cortesi R. Hyaluronan-based microspheres as tools for drug delivery: A comparative study. Int J Pharm 2005;288:35-49.
23. Zubiri D, Monge ME, Negri RM. New kinetic model of drug release from swollen gels under non-sink conditions. Colloids Surf A Physicochem Eng Asp 2006;273:165-73.
24. Zahirul M, Khan I. Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities. Int J Pharm 1996;140:131-43.
25. Nastruzzi C, Esposito E, Cortesi R, Gambari R, Menegatti E. Kinetics of bromocriptine release from microspheres: Comparative analysis between different in vitro models. J Microencapsul 1994;11:565-74.
26. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985;60:110-1.
27. Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1983;15:25-35.
28. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2001;48:139-57.